The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...
Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...
Myeloma UK joined with patients and clinicians to challenge the decision, and today NICE confirmed that Elrexfio will now be ...
The L. family has lived in Massachusetts for several generations on the paternal side. The mother was born in Massachusetts; her parents came from Canada, and 2 of her grandparents were English.
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...
Also make sure to check our part 1 of our exclusive interview with her regarding the recent FDA approval of isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide ...
Ben Crook fought with his partner on their journey to Turkey before going missing, an inquest hears. Kenya's status as a sanctuary for refugees is questioned after the deportation of four Turkish ...
A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...
Combination chemotherapy has been the standard treatment for advanced-stage Hodgkin’s lymphoma for decades. Chemotherapy backbones differ worldwide, with doxorubicin, bleomycin, vinblastine, and ...
Despite these promising results, Nice initially imposed restrictions meaning that anyone who had previously received treatments known as IsaPD – a combination of isatuximab, pomalidomide and ...
Despite these promising results, Nice initially imposed restrictions meaning that anyone who had previously received ...